4.20 0.00 (0.00%)
After hours: 5:12PM EST
|Bid||4.10 x 800|
|Ask||4.98 x 900|
|Day's Range||4.1800 - 4.3000|
|52 Week Range||2.6600 - 29.2500|
|Beta (3Y Monthly)||3.81|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
General counsel for four local public companies signed a letter expressing disappointment in the diversity of law-firm leaders. Those four companies have three female board members, combined.
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of Jounce Therapeutics, Inc. (NASDAQ:JNCE) based on that […]
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 32.35% and 13.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Jounce Therapeutics, Inc. (JNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of 62.16% and 55.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
As Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) closes at new highs, analysts are gushing over the company’s prospects. What is it about Agios stock that has the experts bullish on the company? Markets speculated that Celgene Corporation (NASDAQ:CELG) would buy Agios or Jounce Therapeutics, Inc. (NASDAQ:JNCE) back in April.
In the wake of recently revealed abstracts from the 2018 ASCO meeting, Jounce therapeutics (NASDAQ:JNCE) stock price recently took a significant haircut, but was the drop justified? The goal of the therapy is to tip the balance between these two subtypes of T-cells towards the effector cells by depleting T-regs through antibody activity (ADCC) and encouraging growth of T-effector cells which express ICOS.
Wells Fargo Securities analyst Jim Birchenough downgraded Jounce from Outperform to Market Perform and lowered the price target from $37 to $13. The overall response rate for JTX-2011 as a monotherapy in gastric cancer and triple negative breast cancer, and for the JTX-2011-Opdivo combo in gastric cancer and TNBC, is underwhelming, Birchenough said in a Thursday note.
Shares of Jounce Therapeutics and Sangamo Therapeutics were both hit hard last week by the marketwide sell-off. This dip is likely to prove temporary in both cases, however.